Clinical comparison between improved double regimen and standard quadruple regimen for Helicobacter pylori

doi:10.3877/cma.j.issn.2095-7157.2023.02.005

Abstract

Abstract:

Objective

To study clinical application value of Vonoprazan combined with amoxicillin for 7 day regimen of Helicobacter pylori eradication.

Methods

The clinical data of 100 cases of Hp infection admitted to the Gastroenterology Department of the Fifth Affiliated (Zhuhai) Hospital of Zunyi Medical University were divided into study group (Vonoprazan+ amoxicillin) and control group (Standard quadruple therapy). There were 50 patients in each group. Statistical analysis of Helicobacter pylori eradication, remission of clinical symptoms, occurrence of adverse reactions and cost-effectiveness of the two groups.

Results

The radical cure rate was 94% in the study group and 88% in the control group, the difference was not statistically significant (P>0.05); The remission rate of clinical symptoms in the study group was 84%, Significantly higher than the 62% of the control group, The difference was statistically significant (P<0.05); The incidence of adverse reactions in the observation group was 12%, Significantly lower than the 54% of the control, The difference was statistically significant (P<0.05); The total cost of the study group was 143.02 yuan, and the total cost of the control group was 384.41 yuan, The cost of the study group was significantly lower than that of the control group.

Conclusion

The 7-day regimen containing Vonoprazan and amoxicillin can achieve the eradication rate of standard quadruple, the high remission rate of clinical symptoms, low adverse reactions, low cost, which is more worthy of promotion.

Key words: Vonoprazan, Helicobacter pylori, Amoxicillin, Quadruple regimen

Wenhua Jian, Zhaohui He. Clinical comparison between improved double regimen and standard quadruple regimen for Helicobacter pylori[J]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2023, 10(02): 103-108.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhwcnjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-7157.2023.02.005

https://zhwcnjdzzz.cma-cmc.com.cn/EN/Y2023/V10/I02/103

Figures/Tables 4

References 45

[1]	池肇春．站在新的高度，做好幽门螺旋杆菌感染的防治[J]．世界华人消化杂志，2016，24(16)：2454-2462.
[2]	Teng M，Khoo AL，Zhao YJ, et al.Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori infection[J]．J Clin Pharm Ther，2015，40(4)：368-375.
[3]	Pan W，Zhang H，Wang L，et al.Association between Helicobacter pylori infection and kidney damage in patients with peptic ulcer[J]．Ren Fail，2019，41(1)：1028-1034.
[4]	Gravina AG，Zagari RM，De Musis C，et al.Helicobacter pylori and extragastric diseases：A review[J]．World J Gastroenterol，2018, 24(29)：3204-3221.
[5]	He J，Liu Y，Ouyang Q，et al.Helicobacter pylori and unignorable extragastric diseases：Mechanism and implications[J]．Front Microbiol，2022，13：972777.
[6]	Pellicano R，Ianiro G，Fagoonee S，et al.Review：Extragastric diseases and Helicobacter pylori[J]．Helicobacter，2020，25(Suppl 1)：e12741.
[7]	Lin SY，Lin CL，Liu JH，et al.Association between Helicobacter pylori infection and the subsequent risk of end-stage renal disease: a nationwide population-based cohort study[J]．Int J Clin Pract, 2015，69(5)：604-610.
[8]	Thung I，Aramin H，Vavinskaya V，et al.Review article: the global emergence of Helicobacter pylori antibiotic resistance[J]．Aliment Pharmacol Ther，2016，43(4)：514-533.
[9]	FitzGerald R，Smith SM.An Overview of Helicobacter pylori Infection[J]．Methods Mol Biol，2021，2283：1-14.
[10]	Suzuki S, Esaki M, Kusano C，et al.Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance？[J]. World J Gastroenterol, 2019，25(16)：1907-1912.
[11]	陈珑，焦红梅．基于富马酸伏诺拉生的幽门螺杆菌根除治疗方案的现状[J]．中国临床药理学杂志，2022，38(20)：2506-2509.
[12]	崔璨璨，李长锋，张斌．幽门螺旋杆菌感染治疗方案的研究现状和进展[J]．吉林大学学报(医学版)，2017，43(6)：1287-1290.
[13]	张永芬，昝学凯．消化系统常见疾病与幽门螺杆菌感染的关系探讨[J]．基层医学论坛，2020，24(31)：4468-4469.
[14]	Chey WD，Leontiadis GI，Howden CW, et al.Correction: ACG Clinical Guideline: Treatment of Helicobacter pylori Infection[J]. Am J Gastroenterol，2018，113(7)：1102.
[15]	谢俏，魏晟，董丽凤，等．胃黏膜相关淋巴组织淋巴瘤1例[J]．世界华人消化杂志，2016，24(6)：983-986.
[16]	Malfertheiner P，Megraud F，O′Morain CA, et al.Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report[J]．Gut，2017，66(1)：6-30.
[17]	祝春梅，孙萌潞，徐锦江，等．健康体检人群幽门螺旋杆菌检出结果分析[J]．锦州医科大学学报，2020，41(1)：39-40，46.
[18]	国家消化系疾病临床医学研究中心上海，国家消化道早癌防治中心联盟(GECA)，中华医学会消化病学分会幽门螺杆菌学组，等．中国幽门螺杆菌根除与胃癌防控的专家共识意见(2019年，上海)[J]．中华消化杂志，2019，39(5)：310-316.
[19]	Zizzi CF，Pellicano R，Biancone L．The relationship between Helicobacter pylori and chronic kidney disease：update 2020[J]. Minerva Gastroenterol Dietol，2020，66(4)：343-349.
[20]	朱明飞，赵丽娟，王立军．幽门螺杆菌分型检测及其与幽门螺杆菌根除率的关系研究[J]．西北国防医学杂志，2018，39(9)：606- 610.
[21]	蔡雪梅，胡大春．CYP2C19遗传多态性与药物代谢及疗效的研究进展[J]．当代医学，2012，18(16)：21-23.
[22]	McNicholl AG，Linares PM，Nyssen OP，et al.MetA－analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection[J]．Aliment Pharmacol Ther，2012，36(5)：414-425.
[23]	Hong Y，Dai DP，Cai JP，et al.Effects of Simvastatin on the Metabolism of Vonoprazan in Rats Both in vitro and in vivo[J]. Drug Des Devel Ther, 2022，16(9)：1779-1789.
[24]	Zhou S，Zhao FL，Wang SH，et al.Assessments of CYP-inhibition-based drug-drug interaction between vonoprazan and poziotinib in vitro and in vivo[J]．Pharm Biol, 2023，61(1)：356-361.
[25]	中华医学会消化病学分会.2020年中国胃食管反流病专家共识[J]．中华消化杂志，2020，40(10)：649-663.
[26]	李勉力，张伟健，郭玲珑，等．沃诺拉赞对比质子泵抑制剂治疗反流性食管炎有效性和安全性的Meta分析[J]．中国全科医学，2021，24(6)：712-717.
[27]	张苑，朱晏，刘治恺，等．新型抑酸药物伏诺拉生在幽门螺杆菌治疗中的应用进展[J]．实用医学杂志，2021，37(24)：3218-3222.
[28]	杨桂彬．伏诺拉生和低剂量阿莫西林组成的二联7 d方案是潜在新的一线幽门螺杆菌治疗方案[J]．中华医学杂志，2020，100 (30)：2382.
[29]	陈剑．伏诺拉生与阿莫西林二联治疗幽门螺杆菌感染胃溃疡的疗效和安全性[J]．中国实用医药，2021，16(1)：125-127.
[30]	许文涛，许向波，任天舒，等．伏诺拉生在幽门螺杆菌根除治疗中的作用研究进展[J]．解放军医学杂志，2022，47(9)：947-953.
[31]	Graham DY，Lu H，Shiotani A．Vonoprazan-containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance[J]．J Gastroenterol Hepatol，2021，36(5)：1159-1163.
[32]	Maruyama M，Tanaka N，Kubota D，et al.Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication：A Randomized Controlled Trial[J]．Can J Gastroenterol Hepatol，2017，2017：4385161.
[33]	刘文忠，谢勇，成虹，等．第四次全国幽门螺杆菌感染处理共识报告[J]．胃肠病学，2012，17(10)：618-625.
[34]	朱琦，刘文忠．幽门螺杆菌感染处理的当代概念Maastricht Ⅲ共识报告[J]．中华消化杂志，2007，27(4)：257-261.
[35]	游航．含铋剂四联方案根除幽门螺杆菌治疗失败的危险因素分析[D] .山东大学，2020.
[36]	Ikuse T，Blanchard TG，Czinn SJ.Inflammation, Immunity，and Vaccine Development for the Gastric Pathogen Helicobacter pylori[J]．Curr Top Microbiol Immunol，2019，21(4)：1-19.
[37]	Savoldi A，Carrara E，Graham DY, et al.Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and MetA－analysis in World Health Organization Regions[J]. Gastroenterology，2018，155(5)：1372-1382.
[38]	中华医学会消化病学分会幽门螺杆菌学组.2022中国幽门螺杆菌感染治疗指南[J]．中华消化杂志，2022，42(11)：745-756.
[39]	Kadkhodaei S，Siavoshi F，Akbari Noghabi K．Mucoid and coccoid Helicobacter pylori with fast growth and antibiotic resistance[J]. Helicobacter，2020，25(2)：126-128.
[40]	郑攀．高耐药形势下如何提高幽门螺杆菌的根除率[J]．中国实用内科杂志，2022，42(2)：324-329.
[41]	韩莹莹，方丹，官佳轮，等．阿莫西林和质子泵抑制剂二联治疗幽门螺杆菌感染的研究进展[J]中华消化杂志，2022，42(2)：137-140.
[42]	Sugimoto M，Furuta T．Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype[J]．World J Gastroenterol, 2014，20(21): 6400- 6411.
[43]	陈团生，陈孝敏．伏诺拉生对幽门螺杆菌阳性消化性溃疡患者的疗效、安全性、复发率及生活质量的影响[J]．中外医学研究，2021，19(23)：163-165.
[44]	Graham DY，Lu H，Yamaoka Y．A report card to grade Helicobacter pylori therapy[J]．Helicobacter，2007，12(4)：275-278.
[45]	王丽娜，张田，曹娅，等．伏诺拉生根除幽门螺杆菌感染的快速卫生技术评估[J]．临床药物治疗杂志，2022，20(10)：17-22.

组别	例数	根除率(%)	χ²值	P值
研究组	50	47 (94)	0.488	0.485
对照组	50	44 (88)

组别	例数	根除率(%)	χ²值	P值
研究组	50	47 (94)	0.488	0.485
对照组	50	44 (88)

分组	例数	临床缓解例数			缓解率(%)
分组	例数	显效	有效	无效	缓解率(%)
研究组	50	15	27	8	84
对照组	50	7	24	19	62
χ²值			5.074
P值			0.024

分组	例数	临床缓解例数			缓解率(%)
分组	例数	显效	有效	无效	缓解率(%)
研究组	50	15	27	8	84
对照组	50	7	24	19	62
χ²值			5.074
P值			0.024

不良反应	研究组(例)	对照组(例)	χ²值	P值
口苦	0	17
腹泻	0	5
恶心呕吐	2	1
食欲减退	0	0
吞咽困难	0	0	19.996	<0.001
皮疹	3	2
头晕	1	1
头痛	0	1
肝功能异常	0	0
PP(%)	6/50(12)	27/50(54 )

Please choose a citation manager

Content to export